210 related articles for article (PubMed ID: 23714705)
1. Uterine leiomyosarcoma: an updated series.
Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma.
Rauh-Hain JA; Hinchcliff EM; Oduyebo T; Worley MJ; Andrade CA; Schorge JO; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2014 Oct; 24(8):1434-40. PubMed ID: 25248114
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
4. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
5. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
[TBL] [Abstract][Full Text] [Related]
6. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
7. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases.
Mayerhofer K; Obermair A; Windbichler G; Petru E; Kaider A; Hefler L; Czerwenka K; Leodolter S; Kainz C
Gynecol Oncol; 1999 Aug; 74(2):196-201. PubMed ID: 10419731
[TBL] [Abstract][Full Text] [Related]
8. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
[TBL] [Abstract][Full Text] [Related]
10. Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up.
Singh N; Al-Ruwaisan M; Batra A; Itani D; Ghatage P
J Obstet Gynaecol Can; 2020 Dec; 42(12):1483-1488. PubMed ID: 32900677
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
[TBL] [Abstract][Full Text] [Related]
12. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
14. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
15. Impact of adjuvant treatment on oncologic outcomes in patients with stage I leiomyosarcoma of the uterus.
Boyraz G; Başaran D; Salman MC; Özgül N; Yüce K
Turk J Med Sci; 2017 Jun; 47(3):841-846. PubMed ID: 28618731
[TBL] [Abstract][Full Text] [Related]
16. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
17. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.
Bekos C; Grimm C; Brodowicz T; Petru E; Hefler L; Reimer D; Koch H; Reinthaller A; Polterauer S; Polterauer M
Sci Rep; 2017 Nov; 7(1):14474. PubMed ID: 29101329
[TBL] [Abstract][Full Text] [Related]
19. Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases.
Lim D; Wang WL; Lee CH; Dodge T; Gilks B; Oliva E
Gynecol Oncol; 2013 Feb; 128(2):322-6. PubMed ID: 23153591
[TBL] [Abstract][Full Text] [Related]
20. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]